Pressio, Inc.
Government Contracts & Awards
Electromagnetic Spectrum (EMS) Services, Applied Engineering, & Mobile Services Provider (MSP) Support
$29,077,641Proprietary Tech & Patents
No patents found in our USPTO sample (a narrow, keyword-clustered feed of recent grants in strategic tech sectors — not a comprehensive patent database).
Form D Funding
Private Placement
Market Intelligence & News
NVIDIA Just Hit a New Buy Point. Morgan Stanley Raised Its Target. Where Does It End?
Morgan Stanley just raised its NVIDIA target as the stock closes in on all-time highs, but margin compression and a $50 billion financing controversy raise real questions about how much runway this rally has left.
By 1873, The Railroad Boom Had Built Some Of The Largest Fortunes In American History. Then A Brutal Crash Bankrupted More Than 100 Railroads And Brought A 5-Year Depression. Now, Brookings Projects The AI Buildout Will Be An Even Larger Share Of The Economy Than The Railroad Mania
Jay Cooke's bank failure in 1873 wiped out more than a hundred railroads and triggered a five-year depression, and a new Brookings paper argues the AI buildout dwarfs that spending frenzy as a share of the economy.
The S&P 500 Is Near an All-Time High but Trading at Its Lowest Valuation in a Year. Nvidia, Alphabet, and Amazon Help Explain Why.
S&P 500 earnings are growing faster than stock prices, leading to multiple compression.
Nike's Win Now Plan Is For Patient Investors Willing To Win Later
Nike's margin compression reflects operational deleverage during its strategic shift away from DTC. Click here to read an analysis of NKE stock now.
J&J and Contineum’s Depression Drug Missed Phase 2 Goal. What Comes Next?
Contineum Therapeutics, Inc. (NASDAQ:CTNM) has received the result biotech investors never want to see: one of its partnered drugs missed the primary endpoint of a Phase 2 trial. JNJ-5120/PIPE-307, which Contineum developed and Johnson & Johnson (NYSE:JNJ) is advancing under a global license and development agreement, failed to demonstrate the required efficacy in the Phase […]
Apple building M8 AI servers, talks with Nvidia, reports The Information
Nvidia (NASDAQ: NVDA), which dominates the AI server market and earns roughly a fifth of its data-centre revenue from networking gear, is the most direct equity expression of that development: any Apple deal to adopt NVLink Fusion would add a new, large-volume customer while simultaneously confirming Nvidia’s strategy of monetising interconnect technology even as rival chips challenge its GPU franchise.
Johnson & Johnson Partner Contineum Slides as Depression Drug Fails
Contineum Therapeutics, Inc. (NASDAQ:CTNM) shares are trading lower on Tuesday as Phase 2 results from a key study disappoint. The pullback lines up with a risk-off tone in futures, but the company-specific clinical update appears to be the main driver. CTNM Stock Drops After Phase 2 MOONLIGHT-1 Results The company said its Phase 2 MOONLIGHT-1 trial did not meet its primary efficacy endpoint for JNJ-5120 / PIPE-307 in major depressive disorder. JNJ-5120/PIPE-307 is being developed by Johnson & J
AI chip sell-off overblown: Zero GPU slowdown after Anthropic essay, analyst says
NVIDIA (NASDAQ: NVDA), the dominant supplier of AI training GPUs and the most direct equity expression of AI infrastructure buildout, sits at the center of the debate, as investors weigh whether Amodei’s public call for measured AI development signals a coming reduction in compute demand.
Johnson & Johnson Partner Contineum Slides as Depression Drug Fails
Contineum Therapeutics shares fall as Phase 2 MOONLIGHT-1 depression trial fails primary endpoint. Partner J&J reviews additional trial data.
Lilly completes acquisition of AtaiBeckley to advance therapies for treatment-resistant depression and other mental health conditions
Eli Lilly and Company (NYSE: LLY) today announced the successful completion of its acquisition of AtaiBeckley Inc. AtaiBeckley is a clinical-stage biopharmaceutical company developing rapid-acting neuroplastogens for mental health conditions, including BPL-003, its lead investigational program for treatment-resistant depression.
Key People
JEREMY BLAIR
Related Person
GAETANO GUGLIELMINO
Related Person
JOHN KENT ELLINGTON
Related Person
MICHAEL PORTER
Related Person
Political Giving
$4,900 given to 2 candidates across 2 disclosed contributions (FEC Schedule A).
Abigail Spanberger
Cynthia Axne
Factual Connections
Connections to other companies, executives, and politicians — sourced from disclosed trades, shared officers/directors, and public filings — are a Pro/Alpha feature.
Upgrade to Pro